Selective targeting of certain protein-protein interactions in apoptosis pathways has been pursued as a new therapeutic approach to the treatment of cancers and other diseases that stem from the dysregulation of the apoptosis process. Ascentage, a global clinical-stage biotechnology company, is at the forefront of the discovery and development of small molecule therapeutics targeting PPIs in apoptosis pathways. We are the only company with active clinical programs targeting all three known classes of key apoptosis regulators. Specifically, our pipeline includes three clinical compounds targeting the Bcl-2 family of proteins: APG-1252 for SCLC, other solid tumors and lymphoma; APG-2575 for B-cell malignancies; and AT-101 for chronic lymphocytic leukemia. Two other apoptosis-targeting candidates include APG-1387 (a pan-IAP inhibitor) and APG-115 (an MDM2-p53 inhibitor). We are also evaluating APG-1387 in China for HBV.
The mechanisms of these compounds are depicted in the illustration below: